Clinical Trials Logo

Filter by:
NCT ID: NCT00839332 Completed - Clinical trials for Pancreatic Neoplasms

A Study for Participants With Pancreatic Cancer

Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether LY2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment for participants with pancreatic cancer.

NCT ID: NCT00837811 Completed - Clinical trials for Rheumatoid Arthritis

An Open Label Extension Study in Participants With Rheumatoid Arthritis

Start date: February 2009
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability of LY2127399 administered as subcutaneous injections for 48 weeks in participants with Rheumatoid Arthritis

NCT ID: NCT00835770 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

ENDORSE
Start date: February 3, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

NCT ID: NCT00831441 Terminated - Clinical trials for Acute Coronary Syndrome

Phase III Acute Coronary Syndrome

APPRAISE-2
Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome

NCT ID: NCT00829855 Completed - Hypertension Clinical Trials

Echocardiographic Evaluation of Hypertensive Acute Pulmonary Edema

Start date: May 2008
Phase: N/A
Study type: Observational

Acute cardiogenic pulmonary edema (ACPE), one of the most severe forms of acute heart failure, represents 5% of hospital admissions. One of the most frequent phenomena encountered during ACPE is hypertensive crisis (hypertensive ACPE) but the mechanisms and causes of hypertensive ACPE are insufficiently understood. Few studies have evaluated the cardiac function during hypertensive ACPE, and these studies used only conventional echocardiography methods. New methods of evaluation of cardiac function in hypertensive ACPE (such as Tissue Doppler imaging) have not been used. The objectives of this study are to evaluate presence and role of the following potential mechanisms of hypertensive ACPE: 1. acute myocardial dysfunction (systolic and diastolic); 2. silent transient myocardial ischemia; 3. acute mechanical left ventricular dyssynchrony; 4. dynamic mitral regurgitation; 5. inter-ventricular interaction. Conventional and Tissue Doppler echocardiography will be used to assess cardiac function.

NCT ID: NCT00828386 Terminated - Clinical trials for Nasopharyngeal Cancers

Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers

NPC2006
Start date: January 2009
Phase: Phase 3
Study type: Interventional

This is a randomized, multicenter, phase III trial comparing induction chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) followed by concurrent chemoradiotherapy to concurrent chemoradiotherapy alone, in nasopharyngeal cancers staged as T2b, T3, T4 and/or with lymph node involvement (≥ N1. The main end point is the event free survival.

NCT ID: NCT00824460 Completed - Clinical trials for Chronic Kidney Disease

Study of Phosphate Levels in Patients With Chronic Kidney Disease

PA21
Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.

NCT ID: NCT00824265 Completed - Clinical trials for Leukaemia, Lymphocytic, Chronic

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Start date: March 12, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).

NCT ID: NCT00822744 Completed - Clinical trials for Major Depressive Disorder

An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients

FIDELIO
Start date: December 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of 3 fixed doses of SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major Depressive Disorder (MDD), based on the 17-item Hamilton Depression Rating Scale. Secondary objectives are: - To evaluate the tolerability and safety of an 8-week treatment with SSR411298 versus placebo in elderly patients with MDD. - To evaluate the effect of SSR411298 on disability, anxiety, cognitive function, sleep, pain and somatic symptoms related to depression, and bone markers. - To assess SSR411298 plasma concentrations. - To assess plasma endocannabinoid concentrations.

NCT ID: NCT00821977 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Start date: November 2008
Phase: Phase 2/Phase 3
Study type: Interventional

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.